Send to

Choose Destination
Bioorg Med Chem Lett. 2018 May 15;28(9):1591-1594. doi: 10.1016/j.bmcl.2018.03.052. Epub 2018 Mar 21.

A new target for Alzheimer's disease: A small molecule SERCA activator is neuroprotective in vitro and improves memory and cognition in APP/PS1 mice.

Author information

Van Andel Research Institute, Grand Rapids, MI 49503, USA.
Neurodon LLC, 9800 Connecticut Dr, Crown Point, IN 46307, USA. Electronic address:


Amongst the cellular cacophony of altered signals in Alzheimer's disease (AD), disrupted Ca2+ homeostasis and consequential endoplasmic reticulum (ER) stress signals have been recognized as key determinants of neuron fate. This altered Ca2+ state is accompanied by a failing sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump, which has been recognized as a causal feature of the underlying disease state. Repair of the Ca2+ dyshomeostasis represents a putative drug target via alleviation of ER stress and rescue of injured neurons, effectively modifying the AD state. Herein, we report a small molecule SERCA activator that rescues brain cells and raises ER Ca2+ in vitro, and shows efficacy in the APP/PS1 double transgenic mouse model of Alzheimer's disease. These results support SERCA activation as a therapeutic target for AD.


Alzheimer’s disease; Drug discovery; ER stress; Medicinal chemistry; Neurodegeneration; SERCA; Small molecules

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center